Laura Cortesi

Reggio Nell'emilia, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 124 publications

Low-Dose Tamoxifen in Noninvasive Breast Neoplasia: Long-Term Results From an Individual-Participant Data Pooled Analysis.

Low-Dose Tamoxifen in Noninvasive Breast Neoplasia: Long-Term Results From an Individual-Participant Data Pooled Analysis.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 31, 2026

Reply to Letter to the Editor on: A. G. Nerlich, J. C. Dewaal, A. Perciaccante, S. Di Cosimo, L. Cortesi, J. Wimmer, S. T. Donnell, R, Bianucci: Did Michelangelo paint a young adult woman with breast cancer in "The Flood" (Sistine Chapel, Rome)? Breast 2024, 78, 103823 by Dr. Paul Gelinsky.

Reply to Letter to the Editor on: A. G. Nerlich, J. C. Dewaal, A. Perciaccante, S. Di Cosimo, L. Cortesi, J. Wimmer, S. T. Donnell, R, Bianucci: Did Michelangelo paint a young adult woman with breast cancer in "The Flood" (Sistine Chapel, Rome)? Breast 2024, 78, 103823 by Dr. Paul Gelinsky.

Journal: Breast (Edinburgh, Scotland)

Published: March 25, 2026

Time to next treatment to evaluate the therapeutic sequence after first- or second-line CDK4/6 inhibitors of hormone receptor-positive, HER2-negative advanced breast cancer in Italy: a retrospective/prospective observational trial GOIRC-04-2019.

Time to next treatment to evaluate the therapeutic sequence after first- or second-line CDK4/6 inhibitors of hormone receptor-positive, HER2-negative advanced breast cancer in Italy: a retrospective/prospective observational trial GOIRC-04-2019.

Journal: ESMO real world data and digital oncology

Published: February 06, 2026

Patient Journey for Triple-Negative Breast Cancer: Optimal Care Pathways vs. Reality of Care in Italian Breast Units.

Patient Journey for Triple-Negative Breast Cancer: Optimal Care Pathways vs. Reality of Care in Italian Breast Units.

Journal: Current oncology (Toronto, Ont.)

Published: December 19, 2025

Impaired glucose tolerance in women with BRCA1 versus BRCA2 pathogenic or likely pathogenic variants: Results from a prospective cohort study.

Impaired glucose tolerance in women with BRCA1 versus BRCA2 pathogenic or likely pathogenic variants: Results from a prospective cohort study.

Journal: Familial cancer

Published: December 15, 2025

Association between risk-reducing salpingooophorectomy and bone health in women with hereditary breast and ovarian cancer syndrome.

Association between risk-reducing salpingooophorectomy and bone health in women with hereditary breast and ovarian cancer syndrome.

Journal: Menopause (New York, N.Y.)

Published: November 18, 2025

CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials.

CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials.

Journal: The Lancet. Oncology

Published: November 07, 2025

DonnaRosa Project: Exploring Informal Communication Practices Among Breast Cancer Specialists.

DonnaRosa Project: Exploring Informal Communication Practices Among Breast Cancer Specialists.

Journal: Current oncology (Toronto, Ont.)

Published: November 05, 2025

Preliminary exploration of radiomic mammographic analysis in triple negative breast cancer related to BRCA profile.

Preliminary exploration of radiomic mammographic analysis in triple negative breast cancer related to BRCA profile.

Journal: Scientific reports

Published: September 16, 2025

The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectives.

The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectives.

Journal: Tumori

Published: September 15, 2025

Transcriptomic deconvolution reveals prognostic immune signatures and immunotherapy-responsive subtypes in male breast cancer.

Transcriptomic deconvolution reveals prognostic immune signatures and immunotherapy-responsive subtypes in male breast cancer.

Journal: Breast cancer research : BCR

Published: September 09, 2025

Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer.

Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer.

Journal: NPJ breast cancer

Published: August 28, 2025

Showing 1-12 of 124

Last Updated: 09/26/2026